Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments like Minoxidil, finasteride, and RU58841, focusing on their effectiveness and side effects. It also highlights the disparity in medical research funding between hair loss and conditions like endometriosis.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

Microneedling can be effective for hair growth, but it is more effective when combined with minoxidil. Finasteride or other DHT suppressants are necessary to prevent hair loss due to male pattern baldness.

The conversation discusses the use of ethanol and propylene glycol (PG) in topical solutions for hair loss treatments, specifically Minoxidil. The user dislikes the texture of PG and questions the ideal ratio and necessity of PG in these solutions.

Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hair growth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.

Topical finasteride is currently more effective than pyrilutamide for hair loss. Combining treatments like topical finasteride and pyrilutamide may enhance results due to different mechanisms.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, latanoprost, tretinoin, dutasteride, and cetirizine, with concerns about effectiveness, cost, and potential side effects. Users express skepticism about the product's price and the combination of multiple compounds.

The user is considering adding microneedling to their current hair loss regimen, which includes 1mg finasteride daily, 1.25mg oral minoxidil twice daily, and Nizoral once a week. Opinions on microneedling's effectiveness vary, but some suggest it could enhance results.

The conversation discusses the use of AlphaInfuse, a micro-infusion system with Panax ginseng and Eclipta prostrata extracts, for hair growth and its comparison to Minoxidil. The original poster seeks personal experiences and evidence of its effectiveness.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

A user discusses a dermatologist-prescribed topical solution for hair loss containing 7% Minoxidil, 0.0125% Tretinoin, and 0.1% Dutasteride, questioning its safety. Responses suggest the concentration is generally safe, though there is skepticism about daily use at high concentrations, and similar products like HairStim and Happy Head are mentioned.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

Monthly microneedling combined with low-dose topical dutasteride shows promising results for hair density and thickness with minimal side effects, especially in the frontal area. Despite its effectiveness, it is not widely discussed or used due to availability and cost concerns.

People are excited about a new hair loss treatment, PP405, and some suggest using Twitter to increase its visibility. Current treatments mentioned include finasteride, minoxidil, and dutasteride, but skepticism remains about the effectiveness of new treatments.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

A new supplement for hair growth combines black rice, prickly pear, and saw palmetto, showing promising results in increasing hair density and reducing hair loss. The supplement is considered a drug-free alternative to traditional treatments like minoxidil and finasteride.

Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.

The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.

Some users maintained hair gains after stopping microneedling while continuing minoxidil and finasteride, while others saw no improvement or experienced hair breakage. One user switched to oral minoxidil and continued finasteride and dutasteride after seeing no results from microneedling.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

Nizoral shampoo effectively reduces scalp itchiness and dandruff, particularly for those using minoxidil, and may promote hair growth despite not being FDA-approved for this purpose. Users report significant improvements in scalp health and reduced itchiness with regular use.

RootBioTec, a basil hairy root extract, claims to reduce hair loss by 31% in two months by inhibiting 5α reductase II and stimulating hair follicles. There is limited independent information available about its effectiveness.

A female with PCOS and androgenetic alopecia is starting treatment with oral Minoxidil, topical Minoxidil 5% with finasteride, and plans to add mesotherapy. She previously tried anti-androgenic contraceptive pills but couldn't tolerate them and is using Myo Inositol for weight management.

Topical finasteride can be as effective as oral finasteride for hair regrowth with fewer systemic side effects, but precise dosing is essential. Combining oral dutasteride with topical finasteride is not recommended due to dutasteride's stronger inhibition.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.